CN114796442A - A composition containing plant extract for treating scar and its product - Google Patents
A composition containing plant extract for treating scar and its product Download PDFInfo
- Publication number
- CN114796442A CN114796442A CN202110563277.5A CN202110563277A CN114796442A CN 114796442 A CN114796442 A CN 114796442A CN 202110563277 A CN202110563277 A CN 202110563277A CN 114796442 A CN114796442 A CN 114796442A
- Authority
- CN
- China
- Prior art keywords
- extract
- treatment composition
- parts
- scar treatment
- diethanolamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 239000000419 plant extract Substances 0.000 title claims abstract description 56
- 239000002674 ointment Substances 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 41
- 235000013343 vitamin Nutrition 0.000 claims abstract description 39
- 239000011782 vitamin Substances 0.000 claims abstract description 39
- 229940088594 vitamin Drugs 0.000 claims abstract description 39
- 229930003231 vitamin Natural products 0.000 claims abstract description 39
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 34
- 150000004676 glycans Chemical class 0.000 claims abstract description 33
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 33
- 239000005017 polysaccharide Substances 0.000 claims abstract description 33
- 229920001661 Chitosan Polymers 0.000 claims abstract description 23
- 229920000615 alginic acid Polymers 0.000 claims abstract description 23
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 22
- 241000206572 Rhodophyta Species 0.000 claims abstract description 21
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 4
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 4
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 4
- 229920002101 Chitin Polymers 0.000 claims abstract description 4
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 4
- 229940082787 spirulina Drugs 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 59
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 30
- 244000000626 Daucus carota Species 0.000 claims description 26
- 235000002767 Daucus carota Nutrition 0.000 claims description 26
- 239000003906 humectant Substances 0.000 claims description 26
- 239000002562 thickening agent Substances 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 25
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 24
- 235000012907 honey Nutrition 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 21
- 235000020691 dandelion extract Nutrition 0.000 claims description 20
- 229940067866 dandelion extract Drugs 0.000 claims description 19
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 19
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- -1 safflower extract Substances 0.000 claims description 16
- 235000020694 echinacea extract Nutrition 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 230000003750 conditioning effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 8
- 239000003240 coconut oil Substances 0.000 claims description 8
- 235000019864 coconut oil Nutrition 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 claims description 6
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003760 tallow Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 239000008236 heating water Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 3
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims description 3
- MOUZJOLAMBUMFE-KTKRTIGZSA-N (Z)-N-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCOCCOCCO MOUZJOLAMBUMFE-KTKRTIGZSA-N 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- JFSQSDAOQLNSQI-DTBJPNGVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-(hexadecanoylamino)-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O JFSQSDAOQLNSQI-DTBJPNGVSA-N 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000213006 Angelica dahurica Species 0.000 claims description 3
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims description 3
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 claims description 3
- JHIXEZNTXMFXEK-UHFFFAOYSA-N N-(tetradecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCC(=O)NCCO JHIXEZNTXMFXEK-UHFFFAOYSA-N 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims description 3
- 229940022757 asiaticoside Drugs 0.000 claims description 3
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- 235000020688 green tea extract Nutrition 0.000 claims description 3
- 229940094952 green tea extract Drugs 0.000 claims description 3
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 3
- 229940116335 lauramide Drugs 0.000 claims description 3
- 229940069445 licorice extract Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 3
- 229940049964 oleate Drugs 0.000 claims description 3
- 229940077272 palmitoyl hexapeptide-12 Drugs 0.000 claims description 3
- 239000001967 plate count agar Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229940119485 safflower extract Drugs 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 229940037312 stearamide Drugs 0.000 claims description 3
- 229940045136 urea Drugs 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- CKNOIIXFUKKRIC-HZJYTTRNSA-N (9z,12z)-n,n-bis(2-hydroxyethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)N(CCO)CCO CKNOIIXFUKKRIC-HZJYTTRNSA-N 0.000 claims 1
- 229940058015 1,3-butylene glycol Drugs 0.000 claims 1
- ZAYHEMRDHPVMSC-UHFFFAOYSA-N 2-(octadecanoylamino)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCOC(=O)CCCCCCCCCCCCCCCCC ZAYHEMRDHPVMSC-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229940032977 isostearic diethanolamide Drugs 0.000 claims 1
- XHUUHJFOYQREKL-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-16-methylheptadecanamide Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)N(CCO)CCO XHUUHJFOYQREKL-UHFFFAOYSA-N 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000000638 stimulation Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 24
- 125000003118 aryl group Chemical group 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 12
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical group OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 9
- BVTHRGZMQHOCOL-UHFFFAOYSA-N OCC(O)(C1(NC(=O)NCNC(=O)NC2(CO)NC(=O)NC2=O)NC(=O)NC1=O)CO Chemical group OCC(O)(C1(NC(=O)NCNC(=O)NC2(CO)NC(=O)NC2=O)NC(=O)NC1=O)CO BVTHRGZMQHOCOL-UHFFFAOYSA-N 0.000 description 8
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 8
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 8
- 244000060011 Cocos nucifera Species 0.000 description 6
- 235000013162 Cocos nucifera Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000014134 echinacea Nutrition 0.000 description 5
- 240000004530 Echinacea purpurea Species 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940045811 echinacea purpurea extract Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 125000005645 linoleyl group Chemical group 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
The invention provides a scar treatment composition containing plant extracts and a product thereof, wherein the scar treatment composition comprises the following raw materials: 3-10 parts of plant extract, 1 part of polypeptide and 0.5-1 part of vitamin. The product is an ointment containing a composition for treating scar, and the saccharide substance comprises at least one of algin, red algae polysaccharide, spirulina polysaccharide, chitin polysaccharide, chitosan and hyaluronic acid. The scar treatment composition containing the plant extract and the product thereof provided by the invention are mild, have no stimulation, have good scar removal effect, good stability and are smooth and comfortable.
Description
Technical Field
The invention relates to the field of skin repair, in particular to a scar treatment composition containing plant extracts and an article thereof.
Background
The skin covers the whole body surface and is one of the largest organs of the human body. Meanwhile, the skin is the first barrier between the human body and the outside, and can protect the human body from external pathogens and the external environment. However, due to various accidents in life, the skin is damaged due to trauma, scald and other reasons, so that skin tissues are seriously damaged and cannot be completely repaired by self, and pigmentation and scar hyperplasia of different degrees can be generated on the surface of the skin. Not only reduces the color value and influences the appearance, but also causes the skin not to effectively protect the human body, reduces the resistance and influences the body health.
At present, a plurality of products for repairing scars exist on the world, but most of the products have an irritation effect on skin wounds, the scar repairing effect is not obvious enough, and the production cost is high. The invention provides a scar treatment composition containing plant extracts and an article thereof, which are mild, have no stimulation, have good scar repair effect, are easy to absorb and have no side effect.
Disclosure of Invention
In order to solve the above technical problems, the first aspect of the present invention provides a scar treatment composition containing plant extracts, wherein the scar treatment composition comprises the following raw materials in parts by weight: 3-10 parts of plant extract, 1 part of polypeptide and 0.5-1 part of vitamin.
As a preferred technical solution, the plant extract includes at least one of asiaticoside extract, licorice extract, green tea extract, echinacea extract, carrot seed extract, birch extract, angelica dahurica extract, safflower extract, dandelion extract and honey extract.
As a preferred technical scheme, the polypeptide comprises at least one of acetyl hexapeptide, palmitoyl pentapeptide-3, acetyl tetrapeptide-5, tripeptide-2, palmitoyl tetrapeptide-3 and palmitoyl hexapeptide-12.
As a preferred technical scheme, the acetyl hexapeptide is acetyl hexapeptide-3 and/or acetyl hexapeptide-8.
The second aspect of the invention provides an ointment containing a scar treatment composition, which comprises, by weight, 1-5 parts of the scar treatment composition, 10-15 parts of a humectant, 8-13 parts of a saccharide substance, 3-8 parts of a conditioner, 3-8 parts of a thickener, 0.05-0.2 part of an antibacterial agent and 5-20 parts of water.
As a preferable technical scheme, the humectant comprises at least one of small molecular alcohol, polyethylene glycol, urea, oleate, ceramide, sodium lactate, xylitol, PCA, amides and collagen.
As a preferable technical scheme, the small molecular alcohol comprises at least one of glycerol, propylene glycol, 1, 3-butanediol and sorbitol.
As a preferred technical scheme, the carbohydrate comprises at least one of algin, red algae polysaccharide, spirulina polysaccharide, chitin polysaccharide, chitosan and hyaluronic acid.
As a preferred technical scheme, the conditioning agent comprises at least one of polydimethylsiloxane, isononyl isononanoate, cetearyl alcohol and glyceryl stearate.
As a preferred technical scheme, the thickening agent is at least one of coconut diethanolamide, coconut monoethanolamide, coconut monoisopropanolamide, coconut amide, lauroyl-linoleyl diethanolamide, lauroyl-myristoyl diethanolamide, isostearyl diethanolamide, linoleyl diethanolamide, myristyl monoethanolamide, oil diethanolamide, palm monoethanolamide, castor oil monoethanolamide, sesame diethanolamide, soybean diethanolamide, stearyl monoethanolamide stearate, stearamide, tallow monoethanolamide, wheat germ diethanolamide, PEG (polyethylene glycol) -3 lauramide, PEG-4 oleamide, and PEG-50 tallow amide.
In a preferred embodiment, the antimicrobial agent is bis (hydroxymethyl) imidazolidinyl urea.
In a third aspect, the present invention provides a method for preparing an ointment containing a scar treatment composition, comprising the steps of:
s1: preparing a scar treatment composition: mixing plant extract, polypeptide and vitamins, and stirring;
s2: heating water to 80-86 deg.C, adding humectant and saccharide, stirring to dissolve, homogenizing, and keeping the temperature for 15-30min to obtain mixture I;
s3: uniformly mixing the thickening agent and the conditioning agent, adding the mixture into the first mixture, and uniformly stirring;
s4: cooling to 40-50 deg.C, adding the scar treatment composition, stirring, adding antibacterial agent, stirring, and discharging.
Has the advantages that:
1) the scar treatment composition containing the plant extract and the product thereof can reduce the hyperplasia of scar skin, repair skin tissues, and have good scar removing effect, quick response and small recurrence.
2) The scar treatment composition containing the plant extract and the product thereof can reduce pigmentation, whiten and moisturize skin and have the skin care effect.
3) The scar treatment composition containing the plant extract and the articles thereof prepared by the invention have the advantages of good stability, good temperature resistance, wide temperature tolerance, small thickness, long service life, lubrication and comfort.
4) The scar treatment composition containing the plant extract and the product thereof prepared by the invention are mild, have no stimulation, have good smell, are low in price and have no toxic or side effect.
Detailed Description
In order to solve the above problems, the present invention provides a scar treatment composition comprising plant extracts, in a first aspect, the scar treatment composition comprises the following raw materials in parts by weight: 3-10 parts of plant extract, 1 part of polypeptide and 0.5-1 part of vitamin.
Plant extracts
The plant extract of the present invention is a substance obtained by extracting or processing a whole plant or a part of a plant as a raw material.
As a preferred technical solution, the plant extract includes at least one of asiaticoside extract, licorice extract, green tea extract, echinacea extract, carrot seed extract, birch extract, angelica dahurica extract, safflower extract, dandelion extract and honey extract.
Preferably, the plant extract includes echinacea extract, carrot seed extract, dandelion extract and honey extract.
Echinacea (Echinacea purpurea) extract contains effective components such as alkylamide, polysaccharides, glycoprotein, etc., and is effective in treating dermatosis such as xerosis and allergy, resisting bacteria and virus, enhancing immunity, and healing wound.
The carrot seed (Latin chemical name: Daucuscarota) extract contains alpha pinene and other components, and the carrot seed essential oil has the characteristics of antibiosis, antifungal, anti-inflammation and antioxidation. Carrot seed extract is useful for treating skin infections and open wounds, and helps to treat infections and prevent infections. Meanwhile, the proliferation of the fibroblasts can be promoted. It also has effect in inhibiting melanocyte activity, and can be used for whitening skin; meanwhile, the moisturizing cream has a good moisturizing effect.
The herba Taraxaci (Taraxacum officinale hand-Mazz) extract is mainly used as antiinflammatory and antioxidant. Has good antibacterial and bacteriostatic effects, and can be used for preventing skin inflammation; meanwhile, the composition can promote the growth of bud cells and the like, eliminate free radicals, resist oxidation and slow down aging.
The honey extract (Latin's name: Mel) has good effects of regulating skin moisture and moisture absorption, and has long-term moisture keeping effect. The honey extract is rich in amino acids, oligosaccharides, organic acids, vitamins, calcium, magnesium, sodium, potassium and other minerals, and is close to natural moisturizing factor NMF in human body. Can supplement natural moisturizing factor lost from human body. The rich organic acid and oligosaccharide can lock water, soften stratum corneum, recover skin elasticity, and repair skin tissue.
Scars are local symptoms inevitably generated in the process of repairing human body wounds, can cause the barrier of the communication of oxygen and nutrient substances of skin tissues, further cause the deformity and the dysfunction of damaged tissues, and cause double-layer wound of the body and the heart of a patient. The plant essence contained in the plant extract can promote the growth of skin cells, repair damaged skin and improve the metabolic activity of the skin, and can repair skin mucosa, regulate the symptoms of skin sensitivity, allergy, pruritus and the like and maintain the stable skin state. The applicant finds that under the combined action of plant extracts, polypeptides and vitamins, particularly plant extracts including echinacea purpurea extracts, carrot seed extracts, dandelion extracts and honey extracts, the scar of the skin can be effectively lightened or even removed, probably because the condition can maximally promote the growth of capillary vessels and nerve fibers of new connective tissues, improve the regular and ordered arrangement of atrophied and broken dislocated collagen fibers in the neogenesis process, ensure the stable blood circulation of the locally injured skin, ensure the elasticity of dermal tissues of the skin to be restored, and gradually restore the uneven scar to the original shape.
More preferably, the weight ratio of the echinacea extract, the carrot seed extract, the dandelion extract and the honey extract is (1-3): (2-6): 1: (0.5-2.4).
The addition of the specific plant extract effectively improves the scar removing capability of the paste, but after the specific plant extract is contacted with saccharides, the glycosylation tendency of the paste is increased, the stability of the paste is reduced, and discoloration and precipitation are easy to occur; the invention unexpectedly discovers that when the weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is (1-3): (2-6): 1: (0.5-2.4), the storage stability of the paste is obviously improved; the guess is that the compatibility of the water phase and the oil phase raw materials is improved under the condition, the active components uniformly act on skin tissues, the generation of intermediate byproducts is reduced, and the stability of the ointment is improved.
Polypeptides
The polypeptide compound has the advantages of high biological activity, easy absorption, safety and no toxicity. The polypeptide has good moisture retention, can promote nutrient substances to permeate into skin, improve skin cells, enhance collagen activity in the cells, and achieve the effect of nourishing the skin.
As a preferred technical scheme, the polypeptide comprises at least one of acetyl hexapeptide, palmitoyl pentapeptide-3, acetyl tetrapeptide-5, tripeptide-2, palmitoyl tetrapeptide-3 and palmitoyl hexapeptide-12.
More preferably, the polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2.
As a preferred technical scheme, the acetyl hexapeptide is acetyl hexapeptide-3 and/or acetyl hexapeptide-8.
The applicant finds that the addition of a specific amount of plant extract improves the scar removing effect of the ointment, but the skin has high dependence on the ointment, and hyperplastic tissues or redness and pruritus easily recur at the affected part after the application is stopped. When the polypeptide is acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2, the stable skin state can still be preserved after the polypeptide is stopped for a period of time after the polypeptide is applied, the guess is that the acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2 reach the interior of the skin deeply under the action of plant extracts, polysaccharides and other substances, small molecules of skin connecting tissues are synthesized by fibroblasts, and the small molecules participate in the stable construction of a new skin matrix, so that the loss of collagen in the skin is prevented, the moistening and stabilizing effects are good, and the scar defect is treated from the root source.
As a preferred technical scheme, the weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is (1-4): (1.5-3): 1.
the repair of the division of epidermal cells in the skin often causes a change in color, on the one hand, the growth of new cells, and on the other hand, redness and purplishment of the affected area caused by wound infection and inflammation. It was further found that the amount of the specific acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2 can inhibit local discoloration of the affected part when the weight ratio of acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2 is (1-4): (1.5-3): 1, the redness and purple formation accompanying the new skin at the affected part are obviously reduced, probably because the protease activity required by pigment synthesis is inhibited under the condition, the synthesis and delivery path of the pigment is blocked, and the abnormal color condition in the skin repair process is relieved.
Vitamin preparation
Vitamins are indispensable nutrients for human bodies, are closely related to human metabolism, and play an important role in human regulation. The types of vitamins are various, and the improvement condition of each vitamin on the skin of a human body is different according to the types of the vitamins.
As a preferred technical scheme, the vitamin is Vc and/or Ve.
As a preferable technical scheme, the weight ratio of the plant extract, the polypeptide and the vitamin is (3-10): 1: (0.5-1).
The applicant researches and finds that the addition of the scar treatment composition improves the scar removal effect of the ointment, but the addition of more oily raw materials causes the ointment to have thick texture, poor spreadability and air permeability and poor experience when the ointment is applied to skin; when the weight ratio of the plant extract, the polypeptide and the vitamin is (3-10): 1: (0.5-1), the scar removing effect is remarkable after the ointment is applied to the skin, meanwhile, the ointment is easy to push away on the surface of the skin, and is fresh and moist, and possibly, the scar treating composition under the condition can be better compatible with an ointment medium consisting of a humectant, a saccharide substance, a thickening agent and the like, the small molecular active substances are distributed in gaps of polymer molecular chains in an interpenetration mode, in the process that the ointment acts on the skin, a conditioner and the humectant with the skin-friendly effect are attached to and permeate the surface layer of the skin, the active substances further act, and the scar treating composition consisting of a specific amount improves the absorption capacity of the skin to the ointment, so that the ointment has better air permeability and ductility.
The second aspect of the invention provides an ointment containing a scar treatment composition, which comprises, by weight, 1-5 parts of the scar treatment composition, 10-15 parts of a humectant, 8-13 parts of a saccharide substance, 3-8 parts of a conditioner, 3-8 parts of a thickener, 0.05-0.2 part of an antibacterial agent and 5-20 parts of water.
Moisture-retaining agent
The moisturizer can help to increase or maintain moisture in the upper layers of the skin and prevent the moisture from evaporating, thereby maintaining proper moisture content in the skin. Generally, humectants can be classified into 3 categories: inorganic, organic and metal-organic humectants. When the humectant is selected, the selection is different according to the difference of the equilibrium hygroscopicity, the dynamic hygroscopicity and the volatility of the humectant.
As a preferable technical scheme, the humectant comprises at least one of small molecular alcohol, polyethylene glycol, urea, oleate, ceramide, sodium lactate, xylitol, PCA, amides and collagen. Preferably, the small molecule alcohol comprises at least one of glycerol, propylene glycol, 1, 3-butanediol and sorbitol.
Saccharide material
The saccharides are polyhydroxy aldehydes, polyhydroxy ketones, and organic compounds that can be hydrolyzed to form polyhydroxy aldehydes or polyhydroxy ketones. The skin also contains a number of carbohydrates, mainly glycogen, glucose and mucopolysaccharides. The saccharides have good protection effect on organisms, and some saccharides have multiple biological activities such as oxidation resistance, aging resistance, moisture retention and the like, so that the polysaccharide has wide application prospect.
As a preferred technical scheme, the carbohydrate comprises at least one of algin, red algae polysaccharide, spirulina polysaccharide, chitin polysaccharide, chitosan and hyaluronic acid.
More preferably, the saccharide substance comprises algin, red algae polysaccharide and chitosan.
The applicant finds that the effect of moisturizing and moistening the skin is improved by adding the saccharide substance into the ointment, but the color change and the deterioration of the ointment are easily caused by adding the saccharide substance and the scar treating composition together, and the ointment is not easy to store for a long time. When the saccharide substances are selected from algin, red algae polysaccharide and chitosan to act together, the stability of the paste is improved, the paste still keeps a uniform and stable storage state after high-low temperature multiple cycles, no color change and precipitation occur, possibly, the effects of resisting oxidation and removing free radicals of the paste are enhanced under the condition, the generation of byproducts in a system is inhibited under the high-low temperature storage condition, the temperature resistance range of the paste is widened, and the storage stability is improved.
As a preferred technical scheme, the weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: (1-3): (2-4).
The applicant has found that when the weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: (1-3): (2-4) in the process, the scar removing effect of the ointment is not only reduced in the area of the scar, but also the newly-born skin is soft and tender and has no scar hyperplasia phenomenon, the supposition is that the repair process of the skin tissue under the condition is controllable, the defects of unevenness and hardness caused by excessive proliferation of fibrous connective tissue are not easy to occur, the specific polysaccharide and the active components in the scar treatment composition are spread on the surface of the affected part under the wrapping of the ointment substrate and are efficiently permeated, the symptoms of qi and blood stasis and hot carbuncle of local tissues of the scar are relieved, the local qi and blood circulation and cell tissue growth of the tissues of the affected part are effectively activated by the specific ointment components, the newly-generated skin is soft and tender after repair, and the treatment effect is remarkable.
Conditioning agent
The conditioner plays an important role in skin and has the effects of whitening, moisturizing, resisting aging, removing scars and the like. Conditioners are a general term, and different conditioners have different specific functions and different choices.
As a preferred technical scheme, the conditioning agent comprises at least one of polydimethylsiloxane, isononyl isononanoate, cetearyl alcohol and glyceryl stearate.
Thickening agent
The thickener can improve physicochemical properties such as viscosity of the paste, and maintain uniform and stable state of the system. There are many substances that can be used as thickeners, and from the functional group, there are electrolytes, alcohols, amides, carboxylic acids, esters, and the like. According to different types and action principles of the thickening agent, the action effect is different.
As a preferred embodiment, the thickener is at least one selected from coconut diethanolamide, coconut monoethanolamide, coconut monoisopropanolamide, coconut amide, lauroyl-linoleyl diethanolamide, lauroyl-myristoyl diethanolamide, isostearyl diethanolamide, linoleyl diethanolamide, myristyl monoethanolamide, oil diethanolamide, palm monoethanolamide, castor oil monoethanolamide, sesame diethanolamide, soybean diethanolamide, stearyl monoethanolamide stearate, stearamide, tallow monoethanolamide, wheat germ diethanolamide, PEG (polyethylene glycol) -3 lauramide, PEG-4 oleamide, and PEG-50 tallow amide.
Antibacterial agent
The antibacterial agent has positive effects on skin problems, can effectively inhibit and eliminate a plurality of bacteria and fungi such as staphylococcus aureus and the like, and prevent invasion to human bodies, and certain antibacterial agents not only have antibacterial effect, but also have important effects on acne removal, scar removal and the like.
In a preferred embodiment, the antimicrobial agent is bis (hydroxymethyl) imidazolidinyl urea.
In a third aspect, the present invention provides a method for preparing an ointment containing a scar treatment composition, comprising the steps of:
s1: preparing a scar treatment composition: mixing plant extract, polypeptide and vitamins, and stirring;
s2: heating water to 80-86 deg.C, adding humectant and saccharide, stirring to dissolve, homogenizing, and keeping the temperature for 15-30min to obtain mixture I;
s3: uniformly mixing the thickening agent and the conditioning agent, adding the mixture into the first mixture, and uniformly stirring;
s4: cooling to 40-50 deg.C, adding the scar treatment composition, stirring, adding antibacterial agent, stirring, and discharging.
The present invention will be specifically described below by way of examples. It should be noted that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention, and that the insubstantial modifications and adaptations of the present invention by those skilled in the art based on the above disclosure are still within the scope of the present invention.
In addition, the starting materials used are all commercially available, unless otherwise specified.
Examples
Example 1
An ointment containing a scar treatment composition comprises, by weight, 4 parts of the scar treatment composition, 13 parts of a humectant, 10 parts of a saccharide, 5 parts of a conditioner, 4 parts of a thickener, 0.1 part of an antibacterial agent and 10 parts of water.
The scar treatment composition comprises the following raw materials: plant extracts, polypeptides and vitamins. The weight ratio of the plant extract, the polypeptide and the vitamin is 8: 1: 0.7.
the plant extracts include Echinacea purpurea (Latin's name: Echinacea purpurea) extract, carrot seed (Latin's name: Daucuscarota) extract, dandelion (Latin's name: Taraxacumingongolicum hand. -Mazz.) extract and honey extract (Latin's name: Mel). The weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is 2: 4: 1: 1.8. the echinacea extract and the dandelion extract were purchased from sienna ruibo biotechnology limited; the carrot seed extract is purchased from Henan Tianfu chemical Co., Ltd; the honey extract was purchased from Hengruikang Biotech limited, Ning county.
The polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2. The acetyl hexapeptide is acetyl hexapeptide-8. The weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is 3: 2: 1. the acetyl hexapeptide-8 and the palmitoyl pentapeptide-3 are purchased from Zhejiang On Tuolaisi Biotechnology GmbH; the tripeptide-2 is available from Dougui chemical Co.
The vitamin is Ve.
The humectant is micromolecular alcohol, and the micromolecular alcohol is 1, 3-butanediol.
The saccharide substance comprises algin, red algae polysaccharide and chitosan. The weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 3. the algin is purchased from Shanghai-sourced phyllobis, Inc.; the red algae polysaccharide is purchased from Qingdao oceanic algae industry group limited company; the chitosan was purchased from Shanghai Aladdin Biotechnology GmbH.
The conditioner is cetostearyl alcohol (CAS number: 67762-27-0). Cetearyl alcohol was purchased from jiuding chemistry.
The thickener is coconut oil diethanolamide (CAS number: 68603-42-9). The coconut oil diethanolamide is purchased from Shanghai Yongye Biotech, Inc.
The antibacterial agent is bis (hydroxymethyl) imidazolidinyl urea (CAS number: 78491-02-8). The bis (hydroxymethyl) imidazolidinyl urea is purchased from Shuangyou daily chemical industry Co., Ltd.
A method for preparing ointment containing scar treatment composition comprises the following steps:
s1: preparing a scar treatment composition: mixing plant extract, polypeptide and vitamins, and stirring;
s2: heating water to 84 ℃, adding the humectant and the saccharide, stirring, dissolving, homogenizing uniformly, and keeping the temperature for 25min to obtain a first mixture;
s3: uniformly mixing the thickening agent and the conditioning agent, adding the mixture into the first mixture, and uniformly stirring;
s4: cooling to 45 deg.C, adding the scar treatment composition, stirring, adding antibacterial agent, stirring, and discharging.
Example 2
An ointment containing a scar treatment composition comprises, by weight, 5 parts of the scar treatment composition, 15 parts of a humectant, 13 parts of a saccharide, 8 parts of a conditioner, 8 parts of a thickener, 0.2 part of an antibacterial agent and 20 parts of water.
The scar treatment composition comprises the following raw materials: plant extracts, polypeptides and vitamins. The weight ratio of the plant extract, the polypeptide and the vitamin is 8: 1: 0.7.
the plant extract comprises Echinacea purpurea extract, carrot seed extract, dandelion extract and honey extract. The weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is 2: 4: 1: 1.8.
the polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2. The acetyl hexapeptide is acetyl hexapeptide-8. The weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is 3: 2: 1.
the vitamin is Ve.
The humectant is micromolecular alcohol, and the micromolecular alcohol is 1, 3-butanediol.
The saccharide substance comprises algin, red algae polysaccharide and chitosan. The weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 3.
the conditioner is cetearyl alcohol.
The thickener is coconut oil diethanolamide.
The antibacterial agent is bis (hydroxymethyl) imidazolidinyl urea.
A method for preparing ointment containing scar treatment composition comprises the following steps:
s1: preparing a scar treatment composition: mixing plant extract, polypeptide and vitamins, and stirring;
s2: heating water to 86 ℃, adding the humectant and the saccharide, stirring, dissolving, homogenizing uniformly, and keeping the temperature for 30min to obtain a first mixture;
s3: uniformly mixing the thickening agent and the conditioning agent, adding the mixture into the first mixture, and uniformly stirring;
s4: cooling to 50 deg.C, adding the scar treatment composition, stirring, adding antibacterial agent, stirring, and discharging.
Example 3
An ointment containing a scar treatment composition comprises, by weight, 4 parts of the scar treatment composition, 13 parts of a humectant, 10 parts of a saccharide, 5 parts of a conditioner, 4 parts of a thickener, 0.1 part of an antibacterial agent and 10 parts of water.
The scar treatment composition comprises the following raw materials: plant extracts, polypeptides and vitamins. The weight ratio of the plant extract, the polypeptide and the vitamins is 3: 1: 0.5.
the plant extract comprises Echinacea purpurea extract, carrot seed extract, dandelion extract and honey extract. The weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is 2: 4: 1: 1.8.
the polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2. The acetyl hexapeptide is acetyl hexapeptide-8. The weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is 3: 2: 1.
the vitamin is Ve.
The humectant is small molecular alcohol. The micromolecular alcohol is 1, 3-butanediol.
The saccharide substance comprises algin, red algae polysaccharide and chitosan. The weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 3.
the conditioner is cetearyl alcohol.
The thickener is coconut oil diethanolamide.
The antibacterial agent is bis (hydroxymethyl) imidazolidinyl urea.
A preparation method of ointment containing the scar treatment composition is the same as the embodiment 1.
Example 4
An ointment containing a scar treatment composition comprises, by weight, 4 parts of the scar treatment composition, 13 parts of a humectant, 10 parts of a saccharide, 5 parts of a conditioner, 4 parts of a thickener, 0.1 part of an antibacterial agent and 10 parts of water.
The scar treatment composition comprises the following raw materials: plant extracts, polypeptides and vitamins. The weight ratio of the plant extract, the polypeptide and the vitamin is 8: 1: 0.7.
the plant extract comprises Echinacea purpurea extract, carrot seed extract, dandelion extract and honey extract. The weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is 3: 6: 1: 2.4.
the polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2. The acetyl hexapeptide is acetyl hexapeptide-8. The weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is 3: 2: 1.
the vitamin is Ve.
The humectant is small molecular alcohol. The micromolecular alcohol is 1, 3-butanediol.
The saccharide substance comprises algin, red algae polysaccharide and chitosan. The weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 3.
the conditioner is cetearyl alcohol.
The thickener is coconut oil diethanolamide.
The antibacterial agent is bis (hydroxymethyl) imidazolidinyl urea.
A preparation method of ointment containing the scar treatment composition is the same as the embodiment 1.
Example 5
An ointment containing a scar treatment composition comprises, by weight, 4 parts of the scar treatment composition, 13 parts of a humectant, 10 parts of a saccharide, 5 parts of a conditioner, 4 parts of a thickener, 0.1 part of an antibacterial agent and 10 parts of water.
The scar treatment composition comprises the following raw materials: plant extracts, polypeptides and vitamins. The weight ratio of the plant extract, the polypeptide and the vitamin is 8: 1: 0.7.
the plant extract comprises Echinacea purpurea extract, carrot seed extract, dandelion extract and honey extract. The weight ratio of the echinacea extract to the carrot seed extract to the dandelion extract to the honey extract is 2: 4: 1: 1.8.
the polypeptides include acetyl hexapeptide, palmitoyl pentapeptide-3, and tripeptide-2. The acetyl hexapeptide is acetyl hexapeptide-8. The weight ratio of the acetyl hexapeptide, the palmitoyl pentapeptide-3 and the tripeptide-2 is 1: 1.5: 1.
the vitamin is Ve.
The humectant is small molecular alcohol. The micromolecular alcohol is 1, 3-butanediol.
The saccharide substance comprises algin, red algae polysaccharide and chitosan. The weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 3.
the conditioner is cetearyl alcohol.
The thickener is coconut oil diethanolamide.
The antibacterial agent is bis (hydroxymethyl) imidazolidinyl urea.
A preparation method of ointment containing the scar treatment composition is the same as the embodiment 1.
Comparative example 1
A specific embodiment of an ointment containing a scar treatment composition is the same as in example 1, except that the scar treatment composition comprises the following raw materials: polypeptides and vitamins. The weight ratio of the polypeptide to the vitamins is 1: 0.7.
comparative example 2
A specific embodiment of an ointment containing a scar treatment composition is the same as in example 1, except that the scar treatment composition comprises the following raw materials: plant extracts and vitamins. The weight ratio of the plant extract to the vitamins is 8: 0.7.
comparative example 3
A specific embodiment of an ointment containing a scar treatment composition is the same as in example 1, except that the weight ratio of the plant extract, polypeptide, and vitamins is 13: 1: 0.7.
comparative example 4
A cream containing a scar treatment composition was embodied in the same manner as in example 1, except that the weight ratio of the echinacea extract, carrot seed extract, dandelion extract and honey extract was 2: 4: 1: 0.1.
comparative example 5
A cream containing a scar treatment composition was embodied in the same manner as in example 1, except that the weight ratio of the echinacea extract, carrot seed extract, dandelion extract and honey extract was 2: 4: 1: 3.
comparative example 6
A cream containing a scar treatment composition was embodied in the same manner as in example 1, except that the weight ratio of the echinacea extract, carrot seed extract, dandelion extract and honey extract was 0.1: 4: 1: 1.8.
comparative example 7
An ointment containing a scar treatment composition is embodied in the same manner as in example 1, except that the polypeptides include acetyl hexapeptide and palmitoyl pentapeptide-3. The weight ratio of the acetyl hexapeptide to the palmitoyl pentapeptide-3 is 3: 2.
comparative example 8
A cream containing a scar treatment composition is embodied in the same manner as in example 1, except that the weight ratio of acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2 is 0.1: 2: 1.
comparative example 9
A cream containing a scar treatment composition is embodied in the same manner as in example 1, except that the weight ratio of acetyl hexapeptide, palmitoyl pentapeptide-3 and tripeptide-2 is 7: 2: 1.
comparative example 10
An ointment containing a scar treatment composition was embodied in the same manner as in example 1, except that the saccharide substance included algin and chitosan. The weight ratio of the algin to the chitosan is 1: 3.
comparative example 11
The specific implementation mode of the ointment containing the scar treatment composition is the same as that of example 1, except that the weight ratio of the algin, the red algae polysaccharide and the chitosan is 1: 2: 1.
comparative example 12
The specific implementation of the ointment containing the scar treatment composition is the same as that in example 1, except that the weight ratio of the algin, the red algae polysaccharide and the chitosan is 0.1: 2: 3.
performance testing
(1) And (3) stability testing: storing the paste at-5 deg.C and 40 deg.C for 3 times, each time for 24 hr, respectively, storing at-5 deg.C for 24 hr, storing at room temperature for 24 hr, storing at 40 deg.C for 24 hr, sequentially circulating for 3 times, and observing its stability.
(2) Sensory experience: 136 volunteers were randomly selected and divided into 17 groups, 3g of the ointment was applied to the inner side of the forearm of the volunteer, and the ointment was applied by looping with the index finger for 10 circles to perform comprehensive evaluation of the feeling of heaviness of the skin. The evaluation scale was a: light and breathable; b: the thickness is thick and the air permeability is poor; c: thick and hot.
Table 1 results of performance testing
| Stability test | Sensory experience | |
| Example 1 | Uniform color, no speckle, and aromatic odor | A |
| Example 2 | Uniform color, no speckle, and aromatic odor | A |
| Example 3 | The color and luster are uniform, no spots are generated,has aromatic odor | A |
| Example 4 | Uniform color, no speckle, and aromatic odor | A |
| Example 5 | Uniform color, no speckle, and aromatic odor | A |
| Comparative example 1 | Uneven color, speck generation, and pungent odor | C |
| Comparative example 2 | Uneven color, speckled appearance, and aromatic odor | C |
| Comparative example 3 | Uniform color, no speckle, and aromatic odor | B |
| Comparative example 4 | Has uneven color, no speckles, and aromatic odor | A |
| Comparative example 5 | Has uneven color, no speckles, and aromatic odor | A |
| Comparative example 6 | Has uneven color, no speckles, and aromatic odor | A |
| Comparative example 7 | Uniform color, no speckle, and aromatic odor | B |
| Comparative example 8 | Uniform color, no speckle, and aromatic odor | B |
| Comparative example 9 | Uniform color, no speckle, and aromatic odor | B |
| Comparative example 10 | Uniform color, speckles, and aromatic odor | A |
| Comparative example 11 | Has uneven color, no speckles, and aromatic odor | A |
| Comparative example 12 | Has uneven color, no speckles, and aromatic odor | A |
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in other forms, and any person skilled in the art may modify or change the technical content of the above disclosure into equivalent embodiments with equivalent changes, but all those simple modifications, equivalent changes and modifications made to the above embodiments according to the technical spirit of the present invention still belong to the protection scope of the present invention.
Claims (10)
1. The scar treatment composition containing the plant extract is characterized by comprising the following raw materials in parts by weight: 3-10 parts of plant extract, 1 part of polypeptide and 0.5-1 part of vitamin.
2. The scar treatment composition containing plant extracts of claim 1, wherein the plant extracts include at least one of asiaticoside, licorice extract, green tea extract, echinacea extract, carrot seed extract, birch extract, angelica dahurica extract, safflower extract, dandelion extract, and honey extract.
3. The scar treatment composition of claim 1, wherein the polypeptide includes at least one of acetyl hexapeptide, palmitoyl pentapeptide-3, acetyl tetrapeptide-5, tripeptide-2, palmitoyl tetrapeptide-3, and palmitoyl hexapeptide-12.
4. An ointment containing a scar treatment composition is characterized by comprising, by weight, 1-5 parts of the scar treatment composition, 10-15 parts of a humectant, 8-13 parts of a saccharide substance, 3-8 parts of a conditioner, 3-8 parts of a thickener, 0.05-0.2 part of an antibacterial agent and 5-20 parts of water.
5. The ointment of claim 4, wherein the moisturizer comprises at least one of a small alcohol, polyethylene glycol, urea, oleate, ceramide, sodium lactate, xylitol, PCA, amides, and collagen.
6. The ointment of claim 4, wherein the small alcohol comprises at least one of glycerin, propylene glycol, 1, 3-butylene glycol, and sorbitol.
7. The ointment of claim 4, wherein the saccharide includes at least one of alginate, red algae polysaccharide, spirulina polysaccharide, chitin polysaccharide, chitosan, hyaluronic acid.
8. The ointment of claim 4, wherein the conditioning agent comprises at least one of dimethicone, isononyl isononanoate, cetearyl alcohol, glyceryl stearate.
9. The ointment of claim 4 comprising a scar treatment composition, the thickening agent is at least one of coconut oil diethanolamide, coconut oil monoethanolamide, coconut oil monoisopropanolamide, cocoamide, lauroyl-linoleoyl diethanolamide, lauroyl-myristoyl diethanolamide, isostearic diethanolamide, linoleoyl diethanolamide, myristyl monoethanolamide, oil diethanolamide, palm monoethanolamide, castor oil monoethanolamide, sesame diethanolamide, soybean diethanolamide, stearic monoethanolamide stearate, stearamide, tallow monoethanolamide, wheat germ diethanolamide, PEG-3 lauramide, PEG-4 oleamide, and PEG-50 tallow amide.
10. A method for preparing an ointment containing a scar treatment composition according to claim 4, comprising the steps of:
s1: preparing a scar treatment composition: mixing plant extract, polypeptide and vitamins, and stirring;
s2: heating water to 80-86 deg.C, adding humectant and saccharide, stirring to dissolve, homogenizing, and keeping the temperature for 15-30min to obtain mixture I;
s3: uniformly mixing the thickening agent and the conditioning agent, adding the mixture into the first mixture, and uniformly stirring;
s4: cooling to 40-50 deg.C, adding the scar treatment composition, stirring, adding antibacterial agent, stirring, and discharging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110563277.5A CN114796442A (en) | 2021-05-24 | 2021-05-24 | A composition containing plant extract for treating scar and its product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110563277.5A CN114796442A (en) | 2021-05-24 | 2021-05-24 | A composition containing plant extract for treating scar and its product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114796442A true CN114796442A (en) | 2022-07-29 |
Family
ID=82526806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110563277.5A Withdrawn CN114796442A (en) | 2021-05-24 | 2021-05-24 | A composition containing plant extract for treating scar and its product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796442A (en) |
-
2021
- 2021-05-24 CN CN202110563277.5A patent/CN114796442A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108785241A (en) | A kind of anti-ageing facial mask of small molecule donkey-hide gelatin essence | |
| CN109998937B (en) | Cosmetic series containing glycerol glucoside (alpha GG) and preparation method thereof | |
| CN110664644B (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| KR102326796B1 (en) | Cosmetic materials composition for skin anti-oxidant and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof | |
| CN112842943A (en) | Itching-relieving moisturizing skin-repairing cream and preparation method thereof | |
| CN111603426A (en) | Moisturizing mask and preparation method thereof | |
| KR20170078947A (en) | Cosmetic composition comprising complex of plant extracts | |
| CN113679640A (en) | Natural nourishing skin-cleaning skin-care acne-removing facial cleansing gel and preparation method thereof | |
| CN113975197A (en) | Composition containing sodium polyglutamate and dressing using composition | |
| CN116196250B (en) | Recombinant collagen freeze-dried mask with repairing effect and preparation method thereof | |
| KR102190166B1 (en) | Composition for improving atopy dermatitis, Atopic dermatitis remedy and Manufacturing method thereof | |
| CN111870541A (en) | Herbal whitening compound composition, mask and preparation method thereof | |
| CN107955756B (en) | Handmade soap and preparation method thereof | |
| KR101876744B1 (en) | A step 3 method for improving skin condition using cosmetic composition comprising a ginseng extract | |
| CN114796442A (en) | A composition containing plant extract for treating scar and its product | |
| CN112057400B (en) | Antiperspirant and preparation method thereof | |
| CN114272190A (en) | Composition containing aloe active compound and preparation method and application thereof | |
| CN113786363A (en) | Formula of tricholoma matsutake soothing and repairing mask and preparation method thereof | |
| CN113599316A (en) | Moisturizing and relieving spray and preparation method thereof | |
| CN112156029A (en) | Camellia oil-control mite-removal amino acid cleansing mousse and preparation method thereof | |
| KR20070022949A (en) | Scrub Material Composition for Massage and the Method thereof | |
| CN111544335A (en) | Essence containing soluble collagen and malachite extract and preparation method thereof | |
| RU2780260C1 (en) | Cosmetic for skin | |
| CN113116753B (en) | Rose essential oil face cream and preparation method thereof | |
| CN116270291B (en) | Odor-removing skin care composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220729 |